Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Novartis Announced Cosentyx Received Expanded Approvals in EU for Use in Childhood Arthritic Conditions

By Charles Gross
Today, 5:36 AM
Novartis today announced the European Commission (EC) has approved Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy1.

NVS

Read More
1 minute read

Novartis Announced New Extension Phase Data Show Nearly 80% of Relapsing Multiple Sclerosis Patients Treated with Kesimpta had No Evidence of Disease Activity After Four Years

By Charles Gross
Today, 5:36 AM
Novartis today announced new data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension showing continuous treatment with Kesimpta® (ofatumumab) significantly increased the odds of achieving no evidence of disease activity (NEDA-3) versus switching from teriflunomide1.

NVS